Hypoalbuminemia is common in patients with severe sepsis and septic shock and is associated with poor outcomes. The use of albumin for resuscitation in this population remains controversial. Despite theoretical benefits to the use of albumin, multiple clinical trials and systematic reviews have failed to demonstrate an outcome benefit. We believe that the use of albumin in the resuscitation of patients with severe sepsis and septic shock is not warranted, given the lack of evidence of outcome benefits and its high cost. We present a few important questions.